Jacobs, L D <br/><br/>
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).  [electronic resource] 

 -  Multiple sclerosis (Houndmills, Basingstoke, England)  Jun 1995 
 - 118-35 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1352-4585 
<br/><br/><label>Standard No.: </label>10.1177/135245859500100210  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antiviral Agents--administration & dosage<br/>Clinical Protocols--standards<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Injections, Intramuscular<br/>Interferon-beta--administration & dosage<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis--drug therapy<br/>Patient Selection<br/>Prospective Studies<br/>Recombinant Proteins--administration & dosage<br/>Research Design<br/>Treatment Outcome